Search / Trial NCT00000839

A Phase I Trial to Evaluate Didanosine (ddI) in HIV-Infected Pregnant Women

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Apply for Trial

Trial Information

Current as of December 03, 2023

Completed

Keywords

Pregnancy Trimester, Third Pregnancy Pregnancy Complications, Infectious Didanosine Acquired Immunodeficiency Syndrome Aids Related Complex

Description

AZT may not be the optimal antiretroviral agent for all pregnant women requiring therapy for HIV infection. Although ddI has been approved for use in HIV-infected adults and older children, the safety and pharmacokinetics of ddI in pregnant women has not yet been determined. Patients receive a single IV dose of ddI on day 1 and pharmacokinetics values are determined. At least 48 hours but no more than 1 week after the IV dose, patients receive an oral dose, and oral pharmacokinetics are obtained for 8 hours. Oral ddI is then administered every 12 hours until labor commences and then after ...

Gender

Female

Eligibility criteria

  • Inclusion Criteria
  • Concurrent Medication:
  • Allowed:
  • Aerosolized pentamidine.
  • IV AZT during labor.
  • Patients must have:
  • HIV infection.
  • CD4 count > 50 and < 350 cells/mm3.
  • AZT intolerance or resistance.
  • Gestational age at least 26 weeks but not more than 36 weeks.
  • Consent of guardian if necessary. The father of the fetus must also provide consent if available after reasonable attempts have been made to contact him.
  • Exclusion Criteria
  • Co-existing Condition:
  • Patients with the following symptoms or conditions are excluded:
  • Multiple gestation.
  • Current obstetrical complication, such as major anomalies, growth retardation, abnormal fluid level, fetal hydrops, or placental abruption (placenta previa is allowed).
  • No access to a participating ACTU.
  • Concurrent Medication:
  • Excluded:
  • Drugs that might aggravate pancreatitis, such as steroids, isoniazid, and parenteral pentamidine.
  • Antiretrovirals other than ddI (although IV AZT is allowed during labor).
  • Patients with the following prior conditions are excluded:
  • History of stillbirth, neonatal loss, or previous infant with anomaly (history of preeclampsia or preterm labor is permitted).
  • History of maternal medical complications including but not limited to malabsorption syndrome, pancreatitis, neurological complications including grade 2 or worse peripheral neuropathy, symptomatic cholelithiasis, or prior active CMV disease requiring ganciclovir or foscarnet.
  • History of poor medical compliance not related to access to medical care.
  • Prior Medication:
  • Excluded:
  • ddI within 24 hours prior to study entry.

Attachments

readout_NCT00000839_2023-12-03.pdf

4.5 MB

NCT00000839_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

San Diego, California, United States

Chicago, Illinois, United States

New Orleans, Louisiana, United States

Newark, New Jersey, United States

Los Angeles, California, United States

Miami, Florida, United States

New York, New York, United States

Durham, North Carolina, United States

San Juan, , Puerto Rico

San Juan, , Puerto Rico

Jacksonville, Florida, United States

New York, New York, United States

New Orleans, Louisiana, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0